Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | NAMPT | P43490 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL15903217 | 0.98 | TSHR (0.74) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| Hydrochloric Acid SCHEMBL11508166 | 0.97 | TSHR (0.72) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL7082686 | 0.92 | TSHR (0.73) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL19028142 | 0.90 | TSHR (0.76) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL1161997 | 0.90 | NAMPT (0.75) | KMT2AGAANAMPTUSP2MAPK1 | |
| SCHEMBL11550165 | 0.88 | TP53 (0.72) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL3918322 | 0.88 | TSHR (0.76) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL1680794 | 0.87 | RAB9A (0.72) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL9309245 | 0.87 | NPC1 (0.72) | TSHRNPC1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL8372128 | 0.86 | TSHR (0.74) | TSHRNPC1SMN1; SMN2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304100-B | Method for synthesizing nicotinamide by 3-methylpyridine | JIUJIANG SHANSHUI TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122094660-A | Composition in the form of an oil-in-water emulsion | — | 2026-05-26 | — | — | CN | claimed |
| EP-4687829-A1 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-02-11 | — | — | EP | claimed |
| US-20250381116-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | OREAL (FR) | 2025-12-18 | — | — | US | claimed |
| US-20250161201-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2025-05-22 | — | — | US | claimed |
| WO-2025091220-A2 | COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION | L'OREAL (FR) | 2025-05-08 | — | — | WO | claimed |
| WO-2025091239-A1 | COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION | L'OREAL (FR) | 2025-05-08 | — | — | WO | claimed |
| EP-4543408-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | L'OREAL (FR) | 2025-04-30 | — | — | EP | claimed |
| CN-119654151-A | Composition for caring skin | 莱雅公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119630382-A | Solubilization of thiopyridone compounds and compositions containing same | 莱雅公司 | 2025-03-14 | — | — | CN | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | claimed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | claimed |
| EP-1367985-A2 | ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-10 | — | — | EP | claimed |
| EP-0896522-B1 | METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND | PROCTER & GAMBLE (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002069916-A2 | ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-09-12 | — | — | WO | claimed |
| US-6383476-B1 | Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent | THE PROCTER & GAMBLE COMPANY | 2002-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161201-A1 | COSMETIC COMPOSITION | CYP19A1, SHBG, HSD17B11 | TSHR 2623/4885NPC1 2375/4885SMN1; SMN2 4266/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | TSHR 172/4885NPC1 1371/4885SMN1; SMN2 411/4885 |
| US-20250381116-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | TBCB, CCNB3, CYP24A1 | TSHR 2123/4885NPC1 2754/4885SMN1; SMN2 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.